Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
37.08
-0.38 (-1.01%)
At close: Mar 6, 2026, 4:00 PM EST
37.80
+0.72 (1.94%)
After-hours: Mar 6, 2026, 7:36 PM EST
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| Protagonist Therapeutics | 46.02M |
| Kymera Therapeutics | 39.21M |
| Arcellx | 22.29M |
| CG Oncology | 4.04M |
| CRISPR Therapeutics AG | 3.51M |
COGT News
- 2 days ago - Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish - Seeking Alpha
- 6 days ago - Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 17 days ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 24 days ago - Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - GlobeNewsWire
- 5 weeks ago - Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 6 weeks ago - Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha